AstraZeneca presents real-world evidence data on hyperkalemia

19 June 2023

AstraZeneca’s (LSE: AZN) real-world evidence (RWE) ZORA study shows the negative consequences of reducing or discontinuing life-saving renin-angiotensin-aldosterone system inhibitor (RAASi) medication in patients experiencing hyperkalemia (HK).

The ZORA study was presented at the European Renal Association (ERA) 2023 Congress in Milan, Italy. It showed that:

ZORA data demonstrates that only one in nine US patients and one in 12 Japanese patients re-initiate life-saving medications after a hyperkalemia event. This can have severe consequences for patients as we know mortality rates doubled for patients with CKD and HF whose RAASi had been down-titrated or discontinued compared to patients on maximum RAASi dose.
Another analysis from ZORA also confirmed that patients that had reduced RAASi treatment following a HK event spent approximately nine more days in hospital compared to patients that had maintained these life-saving medicines.
The data presented highlight the urgent need for practice change in hyperkalemia management to enable better outcomes for cardiorenal patients with CKD.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK